Stewart D. Chipman
Directeur Technique/Scientifique/R&D chez Aequus BioPharma, Inc.
Postes actifs de Stewart D. Chipman
Sociétés | Poste | Début | Fin |
---|---|---|---|
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | Directeur Technique/Scientifique/R&D | 17/09/2009 | - |
President | 17/09/2009 | 10/12/2012 |
Historique de carrière de Stewart D. Chipman
Anciens postes connus de Stewart D. Chipman
Sociétés | Poste | Début | Fin |
---|---|---|---|
The Johns Hopkins University | Corporate Officer/Principal | - | - |
ARQULE, INC. | Corporate Officer/Principal | - | - |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Corporate Officer/Principal | - | - |
AMGEN INC. | Directeur Technique/Scientifique/R&D | - | - |
CTI BIOPHARMA CORP. | Directeur Technique/Scientifique/R&D | 17/09/2009 | - |
Formation de Stewart D. Chipman
Boston University | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Belgique | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 3 |
President | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
AMGEN INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Aequus BioPharma, Inc.
Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | Health Services |
CTI BioPharma Corp.
CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
ArQule, Inc.
ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
- Bourse
- Insiders
- Stewart D. Chipman
- Expérience